A final agreement between the FDA and the pharmaceutical industry on user fees for prescription, generic and biosimilar drugs was submitted for approval by Congress. “At a time of greater budgetary constraint, user fees provide a critical way for leveraging appropriated dollars, ensuring that the FDA has the resources needed to conduct reviews in a timely fashion,” FDA Commissioner Margaret Hamburg said.
FDA’s User Fee Agreement heads to CongressPrevious post: Report: Medtech market in China to reach $5 billion this year Next post: Alkermes and Amylin come down to the wire |
